Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC

Jeevisha Bajaj, Ph.D.

Contact Information

Research Labs

Faculty Appointments



Poorly differentiated aggressive myeloid diseases are often resistant to standard therapy and associated with significantly poor survival in both children and adults. There is thus a significant need for a better understanding of the mechanisms that drive disease progression and for finding novel therapeutic targets. While intrinsic signals that drive myeloid cancer progression are well described, little is known about how interactions with the surrounding microenvironment can control leukemic growth and propagation. The primary goal of the Bajaj lab is to define the role of cancer stem cell interactions with their microenvironment in disease progression. To address these questions, we use genetic mouse models of human disease and primary human patient samples, CRISPR screening, as well as real time imaging techniques. In the long term, these studies will not only add to our understanding of the niche in the development and progression of hematological malignancies, but may also contribute to the design of novel therapies.


Journal Articles

Bajaj J; Hamilton M; Shima Y; Chambers K; Spinler K; Van Nostrand E; Yee B; Blue S; Chen M; Rizzeri D; Chuah C; Oehler V; Broome E; Sasik R; Scott-Browne J; Rao A; Yeo G; Reya T. "An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Staufen2 as a key regulator of myeloid leukemia." Nature Cancer. 2020; 1: 410–422.

Bajaj J, Diaz E, Reya T. "Stem cells in cancer initiation and progression." The Journal of cell biology.. 2020 Jan 6; 219(1)

Bajaj J, Konuma T, Lytle NK, Kwon HY, Ablack JN, Cantor JM, Rizzieri D, Chuah C, Oehler VG, Broome EH, Ball ED, van der Horst EH, Ginsberg MH, Reya T. "CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia." Cancer cell.. 2016 Nov 14; 30(5):792-805. Epub 2016 Oct 27.